Back to top

Analyst Blog

Zacks Equity Research

NVO's Tresiba Approved in Japan

SNY NVO

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Denmark based Novo Nordisk (NVO - Analyst Report) recently announced that its candidate Tresiba (insulin degludec) has received approval in Japan. The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tresiba, a next-generation once-daily basal insulin, for the treatment of type I and type II diabetes.

In August 2012, the First Committee on Drugs of Pharmaceutical Affairs, advisory body of MHLW had passed Tresiba. The company expects to launch Tresiba on the completion of price negotiations in Japan, where Tresiba will be available in Novo Nordisk’s insulin pens, FlexTouch and Penfill.

Novo Nordisk conducted a large late-stage program (BEGIN) with Tresiba. Data from the trials, which studied approximately 10,000 type I and type II diabetes patients, confirmed the safety and efficacy of the drug.

The Japanese approval marks the first approval for Tresiba, which is under regulatory review in several countries including the US, the EU, Switzerland, Canada, South Africa, India, Australia, Brazil, Mexico and Russia. We note that the US Food and Drug Administration (FDA) has scheduled an advisory panel meeting on November 8, 2012. We are encouraged by the approval of Tresiba in Japan. US approval would be a major boost for the company.

Even though Novo Nordisk has a strong portfolio of modern insulin analogues, which includes NovoRapid, NovoMix and Levemir, it is heavily banking on the approval of Tresiba and Ryzodeg (another diabetes candidate under regulatory review) for long-term growth. If approved, we expect the candidates to compete with one of the most commonly prescribed insulins, Sanofi's (SNY - Analyst Report) Lantus (insulin glargine).

Our Recommendation

We have an Outperform recommendation on Novo Nordisk. The stock carries a Zacks #1 Rank (Strong Buy rating) in the short term.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%